Fullerton Fund Management Co Ltd. Has $1.05 Million Holdings in Natera, Inc. $NTRA

Fullerton Fund Management Co Ltd. decreased its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 98.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,228 shares of the medical research company’s stock after selling 297,706 shares during the quarter. Fullerton Fund Management Co Ltd.’s holdings in Natera were worth $1,052,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in Natera by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 12,676,653 shares of the medical research company’s stock worth $2,141,594,000 after buying an additional 282,826 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Natera by 44.3% in the second quarter. JPMorgan Chase & Co. now owns 10,625,785 shares of the medical research company’s stock valued at $1,795,125,000 after acquiring an additional 3,263,822 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Natera by 56.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company’s stock worth $1,490,144,000 after acquiring an additional 3,795,315 shares in the last quarter. Geode Capital Management LLC boosted its position in Natera by 7.0% during the second quarter. Geode Capital Management LLC now owns 2,552,725 shares of the medical research company’s stock valued at $430,640,000 after purchasing an additional 166,768 shares during the last quarter. Finally, Franklin Resources Inc. grew its stake in Natera by 20.6% in the second quarter. Franklin Resources Inc. now owns 1,937,647 shares of the medical research company’s stock valued at $327,346,000 after purchasing an additional 330,696 shares in the last quarter. Institutional investors own 99.90% of the company’s stock.

Insider Buying and Selling

In other Natera news, Director Roy D. Baynes sold 7,668 shares of the company’s stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $223.08, for a total value of $1,710,577.44. Following the transaction, the director directly owned 18,359 shares of the company’s stock, valued at $4,095,525.72. This represents a 29.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Steven Leonard Chapman sold 160,703 shares of the stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $199.96, for a total value of $32,134,171.88. Following the transaction, the chief executive officer owned 144,816 shares in the company, valued at $28,957,407.36. The trade was a 52.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 312,053 shares of company stock valued at $64,527,735 in the last ninety days. 5.63% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on NTRA shares. Morgan Stanley upped their price objective on Natera from $220.00 to $265.00 and gave the stock an “overweight” rating in a research note on Monday, December 1st. Zacks Research lowered shares of Natera from a “hold” rating to a “strong sell” rating in a research report on Monday, October 20th. Royal Bank Of Canada set a $268.00 price objective on shares of Natera and gave the company an “outperform” rating in a research report on Tuesday, September 2nd. Piper Sandler upped their target price on shares of Natera from $220.00 to $230.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. Finally, UBS Group raised their target price on shares of Natera from $218.00 to $280.00 and gave the company a “buy” rating in a research note on Tuesday, November 18th. Fifteen research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and a consensus price target of $225.29.

Natera Price Performance

Shares of NTRA opened at $231.95 on Friday. The firm has a market capitalization of $32.08 billion, a PE ratio of -101.29 and a beta of 1.63. The company’s 50-day moving average is $206.71 and its 200-day moving average is $176.50. Natera, Inc. has a fifty-two week low of $125.38 and a fifty-two week high of $246.90.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). The company had revenue of $592.18 million during the quarter, compared to analyst estimates of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The firm’s quarterly revenue was up 34.7% on a year-over-year basis. During the same quarter last year, the company posted ($0.26) EPS. Analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.